Skip to content
OpenCapital
Get started

OS Therapies OSTX Increase (Decrease) in Accrued Interest Receivable, Net

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M—
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K—
Free cash flow-$3.7M—

Valuation

See full
Market cap$84.62M+65.5%
Enterprise value$103.7M—

Returns & leverage

See full
Return on equity470%—
Debt / equity-1.8×—
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's increase (decrease) in accrued interest receivable, net.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's increase (decrease) in accrued interest receivable, net?
OS Therapies (OSTX) reported increase (decrease) in accrued interest receivable, net of -$6.37K in Q1 2026.